CN112533613A - Repeated RNA as biomarker for tumor immune response - Google Patents

Abstract

Predicting response to immunotherapy in a subject and selecting methods of immunotherapy for treating cancer, eg, cancer of epithelial origin.

Description

Repeated RNA as biomarker for tumor immune response

Priority declaration

This application claims the benefit of U.S. provisional patent application serial No. 62/627,151 filed on 6/2/2018. The entire contents of the foregoing are incorporated herein by reference.

Federally sponsored research or development

The present invention was made with U.S. government support under grant number CA087497 awarded by the National Institutes of Health and grant number 1545935 awarded by the National Science Foundation. The government has certain rights in the invention.

Technical Field

The present invention relates to methods of predicting a response to immunotherapy in a subject and selecting an immunotherapy for treating cancer, e.g., of epithelial origin.

Background

The human genome has a high percentage of non-protein-encoding genomic regions organized as tandem repeats. These genomic regions are typically transcriptionally silent, but may be transcribed in cancer cells. For example, the human centromeric human satellite II (HSATII) sequence has been shown to be overexpressed in epithelial cancers, such as pancreatic cancers, but silent in normal cells (see Prosser et al J. mol. biol.187(2):145-55 (1986); Warburton et al (2008) BMC Genomics 9: 533; and Ting et al (2011) Science 331(6017): 593-6; International publication No. WO 2012/048113 l).

Disclosure of Invention

There is increasing evidence that innate immune pathway activation is critical for response to immunotherapy and overall cancer prognosis. It has been proposed that innate immunity in the tumor microenvironment can be driven by repression of endogenous repeat element RNA. The ability to characterize these types provides a new predictive biomarker for tumor immune responses and provides a mechanistic basis for tumor innate activators.

Accordingly, provided herein are methods of treating cancer in a subject. The method comprises providing a sample comprising cells from the cancer;

detecting the level of repeat RNA (e.g., HSATII, LINE-1, HERV-K, HERV-H) in the cell;

comparing the level of repeat RNA in the sample to a reference level; and

selecting and optionally administering a treatment comprising one or both of: (i) a treatment that reduces the output level of, or increases the level of, repeat RNA in a cell, or (ii) an immunotherapy that reduces tumor protective immunosuppression. In some embodiments, the repeat RNA is HSATII.

In some embodiments, the treatment that reduces the output level of repeat RNA in the cell or increases the level of repeat RNA in the cell is an inhibitory nucleic acid targeting repeat RNA, preferably selected from the group consisting of: locked Nucleic Acid (LNA) molecules, short hairpin rna (shrna) molecules, small inhibitory rna (sirna) molecules, antisense nucleic acid molecules, peptide nucleic acid molecules, and morpholino (a morpholino).

In some embodiments, the treatment that exports or increases the level of repeat RNA in a cell is a Reverse Transcriptase Inhibitor (RTI), preferably selected from the group consisting of: nucleoside analog reverse transcriptase inhibitors, nucleotide analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and combinations thereof. In some embodiments, the nucleoside analog reverse transcriptase inhibitor comprises lamivudine (lamivudine), abacavir (abacavir), zidovudine (zidovudine), emtricitabine (emtricitabine), didanosine (didanosine), stavudine (stavudine), entecavir (entecavir), apraxitabine (apricitabine), cissatudin (cenavedine), zalcitabine (zalcitabine), dexelvucitabine (dexelvucitabine), amdoxovir (amdoxovir), elvucine (elvucitabine), fistulivir (fesinavir), lacilacizivir (racvir), stavudine (stampidine), or a combination thereof. In some embodiments, the non-nucleoside reverse transcriptase inhibitor comprises lesivirine (lersivirine), rilpivirine (rilpivirine), efavirenz (efavirenz), etravirine (etravirine), dolavilin (doravirine), dapivirine (dapivirine), or a combination thereof; or wherein the nucleotide analog reverse transcriptase inhibitor comprises tenofovir alafenamide fumarate (tenofovir disoproxil fumarate), adefovir (adefovir), or a combination thereof.

In some embodiments, the treatment that reduces the output level of repeat RNA or increases the level of repeat RNA in the cell comprises a cytidine analog or a guanosine analog.

In some embodiments, the treatment that reduces the output level of repeat RNA or increases the level of repeat RNA in a cell comprises an HDAC inhibitor; a BET inhibitor; or a DNA hypomethylating agent. In some embodiments, the DNA hypomethylating agent (DNA hypomethylating agent) is azacytidine, decitabine (decitabine), cladribine (cladribine), or a combination thereof; the HDAC inhibitor is suberoylanilide hydroxamic acid (SAHA/Vorinostat/Salisa (Zolinza)), trichostatin A (TSA), PXD-101, depsipeptide, MS-275, MGCD0103, valproic acid, or sodium phenylbutyrate, or the BET inhibitor is (+) -JQ1, I-BET762, OTX015, I-BET151, CPI203, PFI-1, MS436, CPI-0610, CPI-2131235, FT-1101, BAY 8097, INCB054329, TEN-010, GSK2820151, ZEN003694, BAY-299, ABRVBMS-986158, ABBV-075, GS-5829, or PLX 51107.

In some embodiments, the method comprises administering a treatment comprising one or both of: (i) a treatment that reduces the output level of, or increases the level of, repeat RNA in a cell, or (ii) an immunotherapy that reduces tumor protective immunosuppression, followed by administration of a treatment comprising an immunotherapy that enhances anti-tumor immunity to the subject, wherein the initial and subsequent reference levels may be the same or different.

In some embodiments, the immunotherapy that enhances anti-tumor immunity comprises an immunotherapeutic agent selected from the group consisting of: anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CD 137 antibodies, anti-CTLA 4 antibodies, anti-CD 40 antibodies, anti-IL 10 antibodies, anti-TGF- β antibodies, and anti-IL-6 antibodies.

In some embodiments, administration of the treatment results in a reduction in tumor burden in the subject.

In some embodiments, the cancer is an epithelial cancer, such as melanoma, pancreatic cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, ovarian cancer, lung cancer, pancreatic cancer, liver cancer, or urothelial cancer.

In some embodiments, the cancer is pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, or hepatocellular carcinoma.

In some embodiments, the cancer comprises a mutation in tumor protein p53(TP 53). The method can optionally comprise detecting the presence of the mutation in TP53, and selecting a subject based on the presence of the mutation.

Also provided herein is a method of predicting whether a cancer will respond to treatment comprising immunotherapy that enhances anti-tumor immunity. The method comprises providing a sample comprising cells from the cancer; detecting the level of repeat RNA in the cell; and comparing the level of repeat RNA in the sample to a reference level; cancers in which the level of repeat RNA is above or below a reference level may respond to treatment comprising immunotherapy to enhance anti-tumor immunity. In some embodiments, the repeat RNA is HSATII, and the presence of a level of HSATII RNA that is lower than a reference level indicates the presence of CD8+ T cells, and the cancer may respond to treatment comprising immunotherapy to enhance anti-tumor immunity; in some embodiments, the repeat RNA is HERV-H, and the presence of a level of HERV-H RNA above a reference level indicates the absence of FOXP3 cells, and the cancer may respond to treatment comprising immunotherapy that enhances anti-tumor immunity. In some embodiments, the levels of HSATII and HERV-H are determined and a treatment comprising an immunotherapy that enhances anti-tumor immunity is selected and optionally administered to a subject having a cancer with a level of HSATII at or below a threshold and a level of HERV-H above a threshold.

Further, provided herein is a method for predicting whether a cancer will respond to treatment comprising immunotherapy that reduces tumor protective immunosuppression. The method comprises providing a sample comprising cells from the cancer; detecting the level of repeat RNA in the cell; and comparing the level of repeat RNA in the sample to a reference level; cancers in which the level of repeat RNA is above a reference level may respond to immunotherapy comprising reducing tumor protective immunosuppression, inhibitory nucleic acid targeting repeat RNA, or Reverse Transcriptase Inhibitor (RTI), wherein the reverse transcriptase inhibitor is selected from the group consisting of: nucleoside analog reverse transcriptase inhibitors, nucleotide analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and combinations thereof.

Further, provided herein is a method for determining the presence or level of immune cells in a cancer. The method comprises providing a sample comprising cells from the cancer; detecting the level of repeat RNA, e.g., HSATII and/or HERV-H repeat RNA, in the cell; and comparing the level of repeat RNA, e.g., HSATII and/or HERV-H repeat RNA, in the sample to a reference level (e.g., a level in a normal adjacent cell or tissue); wherein: cancers with levels of HSATII repeat RNA above a reference level have CD 8T cells in the cancer; a cancer having CD163 macrophages in the cancer with a level of HSATII repeat RNA equal to or lower than a reference level; cancers with levels of HERV-H repeat RNA above the reference level had FOXP 3T cells.

In some embodiments, the method comprises classifying the cancer as CD8+, CD163+, or FOXP3+ based on the level of HSATII and/or HERV-H in the cell.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims.

Drawings

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the office upon request and payment of the necessary fee.

Fig. 1A and 1B: representative images of colon tumors expressing low HERV-H, HERV-H (in situ hybridization) staining and FOXP3+ Treg cell (immunohistochemistry) (FIG. 1A), and those expressing high HERV-H levels, HERV-H (in situ hybridization) staining and FOXP3+ Treg cell (immunohistochemistry) (FIG. 1B). All images were taken at 400x magnification.

FIG. 2: quantification of intratumoral FOXP3+ Treg cells in low and high tumors of HERV-H. Error bar SD.

Fig. 3A and 3B: representative images of CD8 protein expression (immunohistochemistry) and HSATII RNA (in situ hybridization) staining of colon tumors. FIG. 3A: low HSATII expression was associated with high CD8+ T cell infiltration. FIG. 3B: high HSATII expression was associated with low CD8+ T cell infiltration.

FIG. 4: relative quantification of CD8+ T cells within colon cancer tumors in each field (400x200 μm). After in situ hybridization staining, tumor samples were classified as either high or low expression of HSATII. p-value 0.0004 (unpaired t-test).

Fig. 5A and 5B: representative images of melanoma anti-CTLA 4 (ipilimumab) responders (responders) with low HSATII and high CD 3T cells (fig. 5A), and anti-PD 1 (nivolumab) non-responders with high HSATII and low CD 3T cells (fig. 5B).

FIG. 6: representative images of CD163 protein expression (immunohistochemistry) and HSATII RNA (in situ hybridization) staining of colon tumors show a positive correlation of CD163 macrophages with HSATII RNA.

FIG. 7: relative quantification of CD163+ macrophages within colon cancer tumors in each field (400x200 μm). After in situ hybridization staining, tumor samples were classified as either high or low expression of HSATII. p value < 0.0001.

FIG. 8: representative images of HSATII RNA (in situ hybridization) staining and CD163+ macrophage (immunohistochemistry) staining of Pancreatic Ductal Adenocarcinoma (PDAC) tumors.

FIG. 9: representative images of HSATII (in situ hybridization) staining and CD8+ T cell (immunohistochemistry) staining of Pancreatic Ductal Adenocarcinoma (PDAC) tumors. HSATII negative (upper left panel), low expression (upper right panel), medium expression (lower left panel), and high expression (lower right panel) are shown. Note that with increasing HSATII expression, CD 8T cells decreased.

FIG. 10: relative quantification of CD8+ T cells within PDAC tumors per field (400x200 μm). After in situ hybridization staining, tumor samples were classified as either high or low expression of HSATII (p value <0.0001, unpaired t test).

FIG. 11: representative images of HSATII (in situ hybridization) staining and CD8+ T cell (immunohistochemistry) staining of intrahepatic bile duct carcinoma (ICC) tumors. Tumor samples showing HSATII negative (top left), low expression (top right), medium expression (bottom left), and high expression (bottom right). Note that with increasing HSATII expression, CD 8T cells decreased.

FIG. 12: representative images of HSATII and CD8+ T cell CD8+ T cell staining of hepatocellular carcinoma (HCC) tumors. Tumor samples showing HSATII negative (top left), low (top right), and medium (bottom left). No HCC tumor samples showing high HSATII expression. Note that with increasing HSATII expression, CD8+ T cells decreased.

FIG. 13: relative quantification of CD8+ T cells within ICC tumors per field (400x200 μm). After in situ hybridization staining, tumor samples were classified as either high or low expression of HSATII (p-value 0.0223, unpaired t-test).

FIG. 14A: heatmap of interferon-stimulated (viral defense) gene expression in urothelial cancer dataset from Snyder et al (PLoS med.14, e 1002309).

FIG. 14B: Kaplan-Meier plots of overall survival between patients from high and low clusters of ERV repeats. The association was significant (p ═ 0.012, log rank test).

FIG. 14C: Kaplan-Meier plots of progression free survival between patients from high and low clusters of ERV repeats. The association was significant (p ═ 0.025, log rank test).

Detailed Description

Recent data indicate that repeated RNA expression can drive innate immune responses in a variety of malignancies, including melanoma and colon, pancreatic, breast, liver and lung cancers (Rooney et al, Cell 160,48-61 (2015); Chiapielli et al, Cell 162, 974-.

Described herein are clinical grade RNA-ISH assays and methods for quantifying repeat RNA in cancer by RNA-seq (see appendix 1; Desai et al, JCI Insight 2, e91078 (2017); and Ting et al, Science 331, 593-. Furthermore, computational RNA-seq analysis in the cancer genomic dataset (TCGA) indicates that many of the repeated RNAs are not currently captured by the standard mRNA-seq dataset. The correlation of repeated RNA in the total RNA-seq data was also observed (see appendix 2, and Solovyov et al, bioRxiv, BIORXIV/2017/145946 (2017)).

Described herein are assays for assessing immune infiltration (leukocytes including T cell subsets (CD3, CD4, CD8, FOXP 3); macrophage subsets (CD68, CD 163); B cells (CD 20); NK subsets (CD56, CD16)) by immunohistochemistry, while for assessing repetitive RNA (HSATII, LINE1, HERV-H, and HERV-K) by RNA in situ hybridization (RNA-ISH). We have demonstrated a negative association of HERV-H expression with FOXP3+ regulatory T cells (fig. 1 and 2) (see appendix 1) and of HSATII expression with CD8+ effector T-cells (fig. 3 and 4) (see also appendix 2) in 112 colon cancer groups.

In the field of immunotherapy, CD8+ T cell infiltration has been seen to be generally associated with response to immunotherapy (CTLA4 or PD1/PDL 1). FOXP3+ regulatory T cells were thought to block anti-tumor T cell responses, although there were more conflicts with this data (Manjili MH and Butler SE Immunological investors 2016; Ward-Hartstinger KA and Kemp RA. clinical & Translational Immunology 2017).

We predict that HSATII low tumors are associated with high CD 8T cell infiltration, while HERV-H high tumors are associated with low FOXP3+ cells, the latter responding the most to immunotherapy. As shown herein, HSATII low cancers, including melanoma, respond to immunotherapy, including anti-PD 1/PDL1 and anti-CTLA 4 therapies. Furthermore, high HSATII signaling in cancer is positively correlated with CD163+ tumor-associated macrophages, which are often associated with immunosuppressive or unresponsive tumor microenvironments.

Taken together, these data indicate that repeated RNA expression in tumor cells can be used, for example, in Circulating Tumor Cells (CTCs), exosomes (e.g., extracellular vesicles), fine needle aspiration, or minicore biopsy to provide an assessment of the tumor immune microenvironment. These small biopsies are typically so small that the infiltration status of immune cells cannot be assessed and it cannot be determined whether the tumor is immunologically "hot" or "cold". Thus, these repetitive RNA immune markers are alternatives to the tumor immune microenvironment (surrogates). Since the vast majority of patients receiving immunotherapy drugs are metastatic cancer patients, there are only a few biopsy samples, which is of great significance for cancer.

As used herein, the term "cancer" refers to a pathological disease state characterized, for example, by malignant tumor growth. In some embodiments, the methods described herein result in the delay or inhibition of tumor cell proliferation in a subject. In some embodiments, the methods described herein result in increased tumor cell death or killing in the subject. In some embodiments, the methods described herein result in an inhibition of tumor cell growth or metastasis rate. In some embodiments, the methods described herein result in a reduction in tumor size in the subject. In some embodiments, the methods described herein result in a reduction in tumor burden in the subject. In some embodiments, the methods described herein result in a reduction in the number of metastases in the subject.

As used herein, "prophylactic treatment" refers to reducing the incidence of, or preventing (i.e., reducing the risk of) signs or symptoms of a disease in a subject at risk of developing the disease, and "therapeutic treatment," which means reducing the signs or symptoms of a disease, reducing the progression of a disease, reducing the severity of a disease in a subject diagnosed with the disease.

The presence of cancer, e.g., solid tumors of epithelial origin, e.g., as defined by ICD-O (international classification of disease-oncology) code (revision 3) section (8010) -8790, e.g., early stage cancer, is associated with the presence of a large number of satellites due to increased transcription and processing of satellite repeats in epithelial cancer cells (see, e.g., Ting et al (2011) Science 331(6017): 593-6; Bersani et al (2015) proc. natl.acad.sci.u.s.a.112(49): 15148-53; and U.S. publication No.2017/0198288a1, the entire contents of each of which are expressly incorporated herein by reference).

Predicting response to therapy using levels of repeat RNA and selecting therapy

Applicants have determined a correlation between the level of repetitive RNAs such as HSATII, LINE-1, HERV-K, HERV-H RNA in cancer cells and the presence of a particular immune cell population. As described herein, cancer cells with high HSATII RNA levels were positively correlated with the presence of CD163+ tumor-associated macrophages. Without wishing to be bound by theory, it is believed that high HSATII RNA levels in tumors are associated with output of HSATII RNA (e.g., by exosomes), resulting in the presence of high HSATII RNA levels in the tumor environment (e.g., in exosomes), which attract macrophages and then exert a protective effect, attenuating the anti-tumor immune response. It is expected that these cancers will respond to therapies targeting macrophages or therapies that reduce exosomes to HSATII RNA metastatic levels, resulting in increased HSATII and necrotic cell death in the cells. This then reduces the amount of HSATII RNA output to the macrophages to affect them. Accordingly, the methods described herein may include administering macrophage-targeted therapy to a subject identified as having a cancer with a high HSATII RNA level (i.e., a HSATII RNA level above a selected threshold). In some embodiments, the method may comprise administering to the subject a treatment that reduces the level of HSATII RNA output in the cells/increases the level of HSATII RNA in the cells, e.g., one or more HSATII inhibitory nucleic acids; a reverse transcription inhibitor; DNA hypomethylating agents such as DNMT inhibitors; (ii) a Histone Deacetylase (HDAC) inhibitor; or a bromodomain-containing and exoterminal motif (BET) inhibitor; or therapies that target macrophages, such as CD11b, CSF-1R, CCL2, neuropilin-1, ANG2, IL-4 Ra, IL-13, Fc- γ R, IL-6, IL-6R, TNF-alpha, CD 40. Any of these treatments can be administered alone, together, or simultaneously with each other or another anti-cancer therapy, such as cytotoxic chemotherapy, or prior thereto. In some embodiments, the treatment that reduces the level of HSATII RNA output from the cancer cell and/or the treatment that reduces the level of molecular activity of the macrophage is administered for a time sufficient to alter the HSATII RNA level (e.g., reduce the level of HSATII RNA output in the cell/increase the level of HSATII RNA in the cell) and/or increase the level of the macrophage, e.g., for at least 2 days, 5 days, 7 days, 10 days, 14 days, 18 days, 21 days, 28 days, 30 days, or more, after the subject is determined to have cancer with a high level of HSATII RNA (e.g., using an assay as described herein). Optionally, the HSATII RNA level and/or macrophage level is determined again. Once the level of HSATII in the cells is elevated, the level of HSATII in exosomes in the tumor milieu is reduced, or the level of macrophages is reduced (i.e., above or below a threshold), the methods can include administering a treatment as described herein to a subject having a low cancer of HSATII (i.e., a cancer having a level of HSATII below a threshold).

Low HSATII tumors were associated with the presence of high levels of CD8+ T cell infiltration, and cells with high HERV-H levels were associated with the absence or low levels of Foxp3+ regulatory T cells; accordingly, the methods described herein may include administering a CD8+ targeted therapy, such as an immunotherapy that enhances an anti-tumor response, to a subject identified as having a cancer with a low HSATII RNA level and/or a high HERV-H level.

In some embodiments, the methods described herein are used to treat a subject having a cancer of epithelial origin (i.e., an epithelial cancer). The cancer of epithelial origin may include pancreatic cancer (e.g., pancreatic adenocarcinoma), lung cancer (e.g., non-small cell lung cancer or small cell lung cancer), prostate cancer, breast cancer, renal cancer, ovarian cancer, melanoma, or colon cancer. Satellites have also been shown to be elevated in pre-neoplastic or early stage cancer lesions, including intraductal papillary mucinous tumours (IPMN), pancreatic intraepithelial neoplasia (PanIN), Ductal Carcinoma In Situ (DCIS), Barrett's Espohagus (see, e.g., Sharma (2009) N.Engl. J.Med.361(26): 2548-56; reconnaissance: N Engl J Med.362(15): 1450). Thus, the method is potentially useful for treating early-stage pre-neoplastic cancer as a means of preventing the development of invasive cancer. In some embodiments, the cancer is a microsatellite unstable cancer (e.g., MSI colorectal cancer). In some embodiments, the cancer is a microsatellite-stable cancer (e.g., MSS colorectal cancer). See, e.g., Vilar and Gruber, Nat Rev Clin oncol.3 months 2010; 7(3):153-62.

As used herein, "high repeat RNA level" refers to a level above a reference level or threshold, e.g., a reference representing a statistically-determined threshold, e.g., above which a cancer can be diagnosed or treated using the methods described herein; conversely, "low repeat RNA level" refers to a level below a reference level or threshold; this may be the same or different from a reference level or threshold used to identify cancers with high repeat RNA levels.

In some embodiments, the reference level is a level in a normal cell, e.g., a normal cell adjacent to a cancer cell, e.g., a normal adjacent stromal signal, in the same sample. In some embodiments, a high level is defined as a tumor cell signal that is greater than the signal of normal adjacent stromal cells, while a low level is defined as less than or equal to the tumor cell signal seen in adjacent stromal cells.

Suitable reference levels can be determined by methods known in the art. In some embodiments, the method comprises detecting the presence of a high repeat RNA level, e.g., a repeat RNA level above a threshold, in a sample from the subject, e.g., a biopsy sample comprising tumor cells or tumor tissue from the subject. The level of repetitive RNA can be determined by any method known in the art, including Northern blotting, RNA in situ hybridization (RNA ISH), RNA expression assays, such as microarray analysis, RT-PCR, deep sequencing, cloning, Northern blotting, and real-time quantitative polymerase chain reaction (qRT-PCR) (see international publication No. WO 2012/048113, incorporated herein by reference in its entirety). In some embodiments, instead of detecting the level of highly repetitive RNA, the method comprises detecting the copy number of repetitive DNA. An increase in copy number, and/or an increase in repeat RNA levels, as compared to normal cells, indicates that the cancer is susceptible to the treatment described herein. Thus, the method may comprise detecting and/or identifying a cancer with a high repeat RNA level and/or increased repeat copy number, and/or selecting a subject with a cancer with a high repeat RNA level and/or increased repeat copy number for treatment by the methods described herein.

In some embodiments, the method comprises determining the TP53 status of the cancer, and selecting a cancer having a mutation in the TP53 allele (or not selecting a cancer having wild-type TP 53). The reference genomic sequence of TP53 can be found in NG _017013.2 (range 5001-; NC-000017.11 (range 7668402 and 7687550, referenced GRCh38.p2 original Assembly). The method can include, for example, obtaining a sample comprising cells from the subject by comparing the sequence of TP53 in the sample to a reference sequence, e.g., a reference representing a sequence in a normal (wild-type) or non-cancer cell, or a disease reference representing a sequence in a cell from a cancer, such as a malignant cell, and assessing the sample for the presence of a mutation in TP53 known in the art or described herein. Mutations in TP53 that correlate with sensitivity to treatment using the methods described herein are sequences that differ from a reference sequence (e.g., as provided herein) at more than one position. In some embodiments, the mutation is a mutation known in the art to be associated with cancer. International cancer research institute maintains a database of TP53 mutations found in human cancers, with online access to p53.iarc.fr (R18 edition, 2016 month 4); see also Petitjean et al (2007) hum. Mutat.28(6):622-9 and Bouaoun et al (2016) hum. Mutat.37(9): 865-76. In some embodiments, the mutation is a mutation at codon 175, 245, 248, 249, 273 or 282. See, e.g., Olivier et al (2010) Cold Spring Harb. Perspectrum. biol.2(1): a 001008.

The presence of mutations and/or the level of repetitive RNA and/or the number of repetitive copies in TP53 can be assessed using Methods known in the art, for example, using Polymerase Chain Reaction (PCR), reverse transcriptase polymerase chain reaction (RT-PCR), quantitative or semi-quantitative real-time RT-PCR, digital PCR, i.e., BEAMing (bead, emulsion, amplification, magnetic force), Diehl (2006) Nat Methods 3: 551-; RNase protection assay; northern blotting; various types of nucleic acid sequencing (Sanger, pyrosequencing, next generation sequencing); fluorescence In Situ Hybridization (FISH); or gene arrays/chips); RNA in situ hybridization (RNA ISH); RNA expression assays, such as microarray analysis; multiplex gene expression analysis methods such as RT-PCR, RNA sequencing and oligonucleotide hybridization assays including RNA expression microarrays; quantitative determination of digital barcodes based on hybridization, e.g.

Systems (NanoString Technologies, inc., Seattle, WA; Kulkarni (2011) curr. protoc. mol.biol. chapter 25: unit25b.10), and lysate-based hybridization assays using branched DNA signal amplification, such as QuantiGene 2.0 singleplex and multiplex assays (Affymetrix, inc., Santa Clara, CA; see, e.g., Linton et al (2012) j.mol.diagn.14(3): 223-32); SAGE, high throughput sequencing, multiplex PCR, MLPA, Luminex/XMAP, or branched DNA analysis methods. See, for example, international publication No. WO 2012/048113, which is incorporated herein by reference in its entirety.

In some embodiments, RNA ISH is used. Certain RNA ISH platforms utilize the ability to amplify signals in assays that form branched structures (e.g., branched nucleic acid signal amplification) by branched-chain techniques (e.g., bDNA) of multiple polynucleotides that hybridize to each other. In addition to its high sensitivity, the platform also has minimal non-specific background signal compared to immunohistochemistry (see, e.g., Urbanek et al (2015) int.J.mol.Sci.16(6): 13259-86).

In some embodiments, the assay is U.S. patent nos. 7,709,198, 7,803,541, and 8,114,681; and the bDNA assay described in U.S. publication No. 2006/0263769, which describe the general bDNA method; see, in particular, the' 198 patent at 14:39 to 15: 19. In some embodiments, the methods comprise using a modified RNA In Situ Hybridization (ISH) technique using branched-chain DNA assays to directly detect and assess the level of biomarker mRNA in a sample (see, e.g., U.S. patent No. 7,803,541B 2; Canales et al (2006) nat. biotechnol.24(9): 1115-22; Ting et al (2011) Science 331(6017): 593-6). Kits for performing this assay are commercially available from Affymetrix, inc (e.g., for tissue and cell samples)

ViewRNA assay).

RNA ISH can be used, for example

The ViewRNA technique (Affymetrix, Santa Clara, CA).

ViewRNA ISH is based on branched DNA technology, in which signal amplification is achieved by a series of sequential steps (e.g., in single or double format). Thus, in some embodiments, the methods comprise performing an assay as described in U.S. publication No. 2012/0052498 (which describes a method for detecting nucleic acids and proteins by bDNA signal amplification comprising providing a sample comprising or suspected of comprising a target nucleic acid and a target protein; incubating at least two label extension probes each comprising a different L-1 sequence, an antibody specific for the target protein, and at least two label probe systems with a sample comprising or suspected of comprising a target nucleic acid and a target protein, wherein the antibody comprises a preamplifier probe, and wherein at leastThe two label probe systems each comprise a detectably different label; and detecting a detectably different label in the sample); U.S. publication No. 2012/0004132; U.S. publication No. 2012/0003648 (which describes a method of amplifying a nucleic acid detection signal comprising hybridizing more than one labeled extension probe to a target nucleic acid, hybridizing a preamplifier to more than one labeled extension probe, hybridizing more than one amplicon to a preamplifier, hybridizing more than one labeled spoke probe to more than one amplicon, and hybridizing more than one labeled spoke probe to more than one labeled spoke probe); or U.S. publication No. 2012/0172246 (which describes a method of detecting a target nucleic acid sequence comprising providing a sample comprising or suspected of comprising the target nucleic acid sequence, incubating at least two label extension probes, each comprising a different L-1 sequence, and a label probe system with the sample comprising or suspected of comprising the target nucleic acid sequence, and detecting whether the label probe system is associated with the sample). Each hybridized target-specific polynucleotide probe in turn serves as a hybridization target for a pre-amplicon polynucleotide that in turn hybridizes to more than one amplicon polynucleotide. In some embodiments, more than two target-specific probes (label extenders) are hybridized to the target before the appropriate preamplifiers polynucleotides are bound to the 2 label extenders, but in other embodiments a single label extender may be used with the preamplifiers. Thus, in some embodiments, the method comprises incubating more than one label extender probe with the sample. In some embodiments, the target-specific probes (labeled extenders) are in a ZZ orientation, a cross-shaped orientation, or other (e.g., mixed) orientation; see, for example, fig. 10A and 10B in U.S. publication No. 2012/0052498. Each amplicon molecule provides a binding site for a polynucleotide conjugated to a plurality of detectable label probe oligonucleotides, e.g., chromogens or fluorophores, thereby creating a fully assembled signal amplification "tree" having a plurality of binding sites for label probes; the number of binding sites may vary depending on the structure of the tree and the labeling method used, e.g. ranging from 16 to 64 binding sites up to 3000 to 4000. In some casesIn embodiments, there are 300 to 5000 probe binding sites. The number of binding sites can be optimized to be large enough to provide a strong signal, but small enough to avoid the problems associated with oversized structures, i.e., small enough to avoid steric effects and to enter the fixed/permeabilized cells fairly easily, and to wash out if no target is present, since larger trees will require larger components that may become stuck in the pores of the cells (e.g., pores created during permeabilization, pores of the nucleus) and cause noise, despite subsequent washing steps.

In some embodiments, the labeled probe polynucleotide is conjugated to an enzyme capable of interacting with a suitable chromogen, such as Alkaline Phosphatase (AP) or horseradish peroxidase (HRP). In the case of Alkaline Phosphatase (AP) -conjugated polynucleotide probes, after sequential addition of an appropriate substrate, such as a fast red or fast blue substrate, the AP decomposes the substrate to form a precipitate, allowing in situ detection of specific target RNA molecules. Alkaline phosphatase can be used with a number of substrates, for example, fast Red, fast blue, or 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Thus, in some embodiments, the methods include the use of alkaline phosphatase conjugated polynucleotide probes in bDNA signal amplification methods, e.g., as generally described in U.S. patent nos. 5,780,277 and 7,033,758. Other enzyme and chromogen substrate pairs, such as horseradish peroxidase (HRP) and 3,3' -Diaminobenzidine (DAB), may also be used. Many suitable enzymes and chromogen substrates are known in the art and can be used to provide a variety of colors for the detectable signal produced in the assay, and appropriate selection of the enzyme and substrate used can facilitate multiplexing of targets and labels in a single sample. For these embodiments, the labeled probe can be detected using known imaging methods, for example, bright field microscopy using the CISH method.

Other embodiments include the use of fluorophore-conjugate probes, such as Alexa Fluor dye (Life Technologies Corporation, Carlsbad, California) conjugated to a label probe. In these embodiments, the labeled probe can be detected using known imaging methods, such as fluorescence microscopy (e.g., FISH). Selection of an appropriate fluorophore can also facilitate multiplexing of the target and label based on, for example, the emission spectrum of the selected fluorophore.

In some embodiments, the assay is similar to that described in U.S. publication nos. 2012/0100540, 2013/0023433, 2013/0171621, 2012/0071343; or 2012/0214152 (each of which is incorporated herein by reference in its entirety).

In some embodiments, the RNA ISH assay is performed without the use of bDNA, and the repeat RNA (e.g., HSATII, LINE-1, HERV-K, or HERV-H) or TP 53-specific probes are labeled directly or indirectly (e.g., via an antibody) with one or more labels described herein.

The determination can be performed manually or on an automated instrument, such as a Leica BOND series instrument or a Ventana discover ULTRA or discover XT instrument.

As used herein, a "test sample" refers to a biological sample obtained from a subject of interest, including one or more cells, e.g., tissues, from a tumor. (Lehninger Biochemistry (Worth Publishers, Inc., Current edition); Sambrook et al, Molecular Cloning: A Laboratory Manual, 3 rd edition, 2001, Cold Spring Harbor Laboratory Press, New York; Bernard (2002) Clin. chem.48(8): 1178-85; Miranda (2010) Kidney International 78: 191-9; Bianchi (2011) EMBO Mol Med 3: 495-503; Taylor (2013) Front. Genet.4: 142; Yang (2014) PLoS One 9(11): e 110641); nordstrom (2000) Biotechnol.appl.biochem.31(2): 107-12; ahmandian (2000) anal. biochem.280: 103-10. In some embodiments, high throughput Methods, such as protein or gene chips known in the art (see, e.g., Ch.12, Genomics, Griffiths et al, editors, Modern Genetic Analysis,1999, W.H.Freeman and Company; Ekins and Chu (1999) Trends in Biotechnology 17: 217-8; MacBeath and Schreiber (2000) Science 289(5485): 1760-3; Simpson, Proteins and Proteomics: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 2002; Hardiman, microarray Methods and Applications: ts Nu & Bolts, DNA Press,2003), can be used to detect the presence and/or level of mutations in TP 53.

In some embodiments, techniques suitable for detecting changes in the structure or sequence of a nucleic acid, such as the presence of deletions, amplifications, or substitutions, can be used to detect changes in a repeat RNA (e.g., HSATII, LINE-1, HERV-K, or HERV-H) or TP 53.

In some embodiments, RT-PCR can be used to detect mutations and Copy Number Variants (CNVs). The first step in expression profiling by RT-PCR is to reverse transcribe the RNA template into cDNA, which is then exponentially amplified in a PCR reaction (Ausubel et al (1997) Current Protocols of Molecular Biology, John Wiley and Sons). To minimize the effect of errors and sample-to-sample variation, RT-PCR is typically performed using an internal standard that is expressed at a constant level in tissues and is unaffected by experimental treatments. Housekeeping genes known in the art are most commonly used.

In some embodiments, the method may comprise detecting the protein level of TP53 and comparing the protein level to a reference protein level in normal cells. Mutations in TP53 typically result in reduced protein expression levels, and thus reduced protein expression levels compared to a wild-type reference level or threshold level can be used as a proxy for the mutation status; cancers in which levels of TP53 are reduced may be selected for treatment by the methods described herein (or cancers in which levels of TP53 are normal or not substantially reduced compared to a wild-type reference or threshold may be excluded from treatment by the methods described herein). The level of protein can be assessed using methods known in the art, for example, using standard electrophoresis and quantitative immunoassays for proteins, including but not limited to western immunoblots; enzyme-linked immunosorbent assay (ELISA); biotin/avidin type determination; detecting a protein array; performing radioimmunoassay; immunohistochemistry (IHC); immunoprecipitation assay; FACS (fluorescence activated cell sorting); mass spectra (Kim (2010) am. J. Clin. Pathol.134: 157-62; Yasun (2012) anal. chem.84(14): 6008-15; Brody (2010) Expert Rev. mol. Diagn.10(8): 1013-22; Philips (2014) PLOS One 9(3): e 90226; Pfaffe (2011) Clin. chem.57(5): 675-687). The methods generally include detectable labels that provide a signal, either directly or indirectly, such as fluorescent, chemiluminescent, radioactive, and enzymatic or dye molecules. As used herein, the term "label" refers to the coupling (i.e., physical attachment) of a detectable substance, such as a radioactive agent or a fluorophore (e.g., Phycoerythrin (PE) or indocyanine green (Cy5)) to an antibody or probe, as well as the indirect labeling of the probe or antibody (e.g., horseradish peroxidase, HRP) through reactivity with the detectable substance.

In some embodiments, enzyme-linked immunosorbent assay (ELISA) methods can be used, wherein the wells of the microtiter plate are coated with antibodies to the protein to be tested. A sample containing or suspected of containing the biomarker is then applied to the well. After a sufficient time, during which an antibody-antigen complex will form, the plate is washed to remove any unbound moieties, and detectably labeled molecules are added. Again, after a sufficient incubation time, the plate is washed to remove any excess unbound molecules and the presence of labeled molecules is determined using methods known in the art. Variations of ELISA methods such as competitive ELISA or competitive assays and sandwich ELISA may also be used as they are well known to those skilled in the art.

In some embodiments, Immunohistochemistry (IHC) methods may be used. IHC provides a method for in situ detection of biomarkers. The presence of biomarkers and the exact cellular location can be detected. Typically, a sample (e.g., a biopsy sample) is fixed with formalin or paraformaldehyde, embedded in paraffin, and cut into sections for staining and subsequent examination by light microscopy. Current IHC methods typically use direct or indirect labeling. When Immunofluorescence (IF) is performed, the sample can also be examined by fluorescence microscopy as an altered version of IHC.

Mass spectrometry, particularly matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and surface-enhanced laser desorption/ionization mass spectrometry (SELDI-MS), is useful for detecting the biomarkers of the invention. (see U.S. Pat. Nos. 5,118,937, 5,045,694; 5,719,060; and 6,225,047).

The sample may be, for example, a biopsy, such as a needle biopsy or an excised specimen, taken from a mass known or suspected to be a tumor or cancer.

The reference level or predetermined level may be a single cutoff (threshold), such as a median or mean, or a level as follows: the boundaries of a group, such as the upper and lower quartiles, tertiles, or other portions of a clinical trial population, are defined, i.e., statistically determined to be different from the other portions. It may be a series of cutoff values (or thresholds), such as confidence intervals. Can be determined from comparing groups, e.g., having a higher or lower (e.g., about 2-fold, 4-fold, 8-fold, 16-fold or more) association with the risk of developing a disease or the presence of a disease in one particular group than the association with the risk of developing a disease or the presence of a disease in another particular group. It may be a range, for example, where a population of subjects (e.g., control subjects) is divided equally (or unequally) into groups, e.g., a low risk group, a medium risk group, and a high risk group, or into quartiles, the lowest quartile being the lowest risk subject and the highest quartile being the highest risk subject, or into n quantiles (i.e., n regularly spaced intervals), where the lowest of the n quantiles is the lowest risk subject and the highest of the n quantiles is the highest risk subject.

In some embodiments, the level of the subject is greater than the reference level in an amount sufficient to distinguish the subject from the control subject, and optionally statistically significantly greater than the level of the control subject. Where the copy number in a subject is "equal to" a reference copy number, "equal" refers to approximately equal (e.g., statistically not different).

The predetermined value may depend on a particular population of selected subjects (e.g., human subjects). One of ordinary skill in the art can select the appropriate range and class with only routine experimentation.

In characterizing a likelihood or risk, a number of predetermined values may be established.

The selection of an appropriate route of administration of the treatment will depend on a variety of factors, including but not limited to the particular treatment and/or location of the cancer. In some embodiments, the treatment is administered orally, parenterally, intravenously, topically, intraperitoneally, subcutaneously, intracranially, intrathecally, or by inhalation. In some embodiments, the treatment is administered by continuous infusion.

Reverse Transcriptase Inhibitors (RTI)

Applicants have surprisingly found that HSATII high cancer cells that are refractory to anti-tumor response enhancing immunotherapy become more sensitive when using treatments that reduce immunosuppression. In some embodiments, the treatment comprises administering a Reverse Transcriptase Inhibitor (RTI), e.g., a nucleoside analog reverse transcriptase inhibitor (NRTI), a nucleotide analog reverse transcriptase inhibitor, or a non-nucleoside reverse transcriptase inhibitor (NNRTI). In some embodiments, the treatment comprises a combination of a nucleoside analog reverse transcriptase inhibitor, a nucleotide analog reverse transcriptase inhibitor, and/or a non-nucleoside reverse transcriptase inhibitor. In some embodiments, the treatment does not include NRTI.

Many reverse transcriptase inhibitors are known in the art and can be used as described herein, including Zidovudine (ZDV), didanosine (ddI), stavudine (d4T), zalcitabine (DDC), lamivudine (3TC), Abacavir (ABC), Tenofovir (TDF), emtricitabine (FTC), etravirine lobavir (etravirine lobecavir), Entecavir (ETV), alprostitabine, cissudine, dexelvucitabine, alovudine (alovudine), amdoxovir, elvucine, lacivir, and sitepidine. Additional reverse transcriptase inhibitors are disclosed, for example, in U.S. publication nos. 2017/0267667, 2016/0145255, 2015/0105351, 2007/0088015, 2013/0296382, 2012/0225894, 2012/0053213, 2012/0029192, 2009/0162319, and 2007/0021442, the entire contents of each of which are incorporated herein by reference. Without wishing to be bound by any particular theory, given the high GC content of HSATII, the use of guanosine and cytidine analogs is particularly advantageous for treating cancers comprising high HSATII RNA levels. In some embodiments, the RTI is a cytidine analog (e.g., zalcitabine (ddC); lamivudine (3 TC); and emtricitabine (FTC); in some embodiments, the RTI is a guanosine analog (e.g., Abacavir (ABC) and Etimavir (ETV)).

HDAC inhibitors

In some embodiments, the method comprises administering an HDAC inhibitor, many of which are known in the art, including suberoylanilide hydroxamic acid (SAHA/vorinostat/solisha), trichostatinRhzomorphs a (tsa), and PXD-101 (hydroxamic acid-based pan HDAC inhibitor); depsipeptide (FK 228/romidepsin) based on the presence or absence of a peptide

) (natural cyclic peptide inhibitors of HDAC 1/2); MS-275 and MGCD0103 (which are synthetic benzamide derivatives); and valproic acid and sodium phenylbutyrate (which are relatively inefficient aliphatic acids). See, e.g., Kim and Bae, Am J trans res.2011 month 1; 3(2):166-179.

BET inhibitors

In some embodiments, the methods comprise administering BET inhibitors, many of which are known in the art, including (+) -JQ1, I-BET762, OTX015, I-BET151, CPI203, PFI-1, MS436, CPI-0610, RVX2135, FT-1101, BAY1238097, INCB054329, TEN-010, GSK2820151, ZEN003694, BAY-299, BMS-986158, ABBV-075, GS-5829, and PLX 51107; see, e.g., Perrez-Salvia and Esteller, Epigenetics.2017; 12(5):323-339.

DNA hypomethylating agent

In some embodiments, the methods described herein further comprise administering a DNA hypomethylating agent to the subject. DNA methylation is an epigenetic modification that regulates gene transcriptional silencing. Genomic methylation patterns can be altered in tumors (Smet et al (2010) epidemics 5(3):206-13) and are significant in B Cell malignancies (Debatin et al (2007) Cell 129(5): 853-5; Martin-Subero (2006) Leukemia 20(10): 1658-60). For example, treatment with a DNA hypomethylating agent (e.g., 5-pentaazacytidine), as described below. Without wishing to be bound by any particular theory, it is believed that treatment with a DNA hypomethylating agent activates transcription of HSATII, thereby rendering the cells receptive to NRTI treatment.

In some embodiments, the DNA hypomethylating agent is a DNA methyltransferase inhibitor. In some embodiments, the DNA methyltransferase inhibitor is 5' -azacytidine (Aza), decitabine ((DAC), cladribine (2CdA), or a combination thereof (wyczochrkasa et al (2003) Biochem pharmacol.65: 219-25; Yu et al (2006) am.j.hematol.81(11): 864-9; and Garcia-Manero (2008) curr.opin.oncol.20(6): 705-10.) additional DNA hypomethylating agents are described, for example, in U.S. publication nos. 2011/0218170a1, 2005/0119201, and 2015/0258068, the entire contents of each of which are incorporated herein by reference.

HSATII inhibitory nucleic acids

In some embodiments, the methods described herein comprise further administering to the subject an inhibitory nucleic acid (e.g., an LNA molecule) that specifically targets HSATII. Inhibitory nucleic acids targeting HSATII and methods of use thereof are disclosed, for example, in U.S. publication No.2017/0198288, the entire contents of which are expressly incorporated herein by reference.

Immunotherapeutic agent

In some embodiments, the methods comprise administering an immunotherapeutic agent to a subject identified using the methods described herein. Immunotherapeutics include those therapies that target tumor-induced immunosuppression; see, e.g., Stewart and Smyth (2011) Cancer Metastasis Rev.30(1): 125-40.

Enhancement of CD8+ T cell anti-tumor response

In some embodiments, the methods comprise selecting and/or administering a therapy that enhances an anti-tumor immune response. Examples of immunotherapies that enhance CD8+ cell responses include, but are not limited to, adoptive T cell therapies or Cancer vaccine formulations designed to induce T lymphocytes to recognize Cancer cells, and checkpoint inhibitors such as anti-CD 137 antibodies (e.g., BMS-663513), anti-PD 1 antibodies (e.g., Nivolumab), pembrolizumab/MK-3475, pidilizumab (pidilizumab) (CT-011)), anti-PDL 1 antibodies (e.g., BMS-659359, MPDL3280A), or anti-CTLA-4 antibodies (e.g., ipilimumab (ipilimumab); see, e.g., Krueger et al (2007) Histol Histopatol.22 (6): 687-96; Eggermontmont et al (2010) Sehscol.37 (5): 455-9; Klinzel. 9: AcdrexesJ.242; AldrexesJ.2010. 2010. 23; Achjn et al (2010. 7) and Octeur. J.23. 7. 11. 7: 14; Occidum. J. 23. 11. 7. sub.23; and Nathogel J. 23. 7. 11. J. 7. sub. 7. 9; Occidum. J. 7. et al (Occidum. Nature. 7. A) and Nature. 7 ):342-7).

Exemplary anti-PD-1 antibodies that can be used in the methods described herein include those that bind to human PD-1; NCBI accession No. NP _005009.2 provides an exemplary PD-1 protein sequence. Exemplary antibodies are described in U.S. patent nos. 8,008,449; 9,073,994, respectively; and U.S. publication No. 2011/0271358, including, for example, PF-06801591, AMP-224, BGB-a317, BI 754091, JS001, MEDI0680, PDR001, REGN2810, SHR-1210, TSR-042, pembrolizumab, nivolumab, avilumab (avelumab), pidilizumab, and atelizumab (atezolizumab).

Exemplary anti-CD 40 antibodies that may be used in the methods described herein include those that bind to human CD 40; NCBI accession numbers NP _001241.1, NP _690593.1, NP _001309351.1, NP _001309350.1 and NP _001289682.1 provide exemplary CD40 protein precursor sequences. Exemplary antibodies include international publication nos. WO 2002/088186; WO 2007/124299; WO 2011/123489; WO 2012/149356; WO 2012/111762; WO 2014/070934; U.S. publication No. 2013/0011405; 2007/0148163, respectively; 2004/0120948, respectively; 2003/0165499, respectively; and U.S. patent No. 8,591,900; including, for example, those described in daclizumab (dacetuzumab), lucatumumab (lucatumumab), breleslutumab (bleselumab), tenecteximab (teneliximab), ADC-1013, CP-870893, Chi Lob 7/4, HCD122, SGN-4, SEA-CD40, BMS-986004, and APX 005M. In some embodiments, the anti-CD 40 antibody is a CD40 agonist, but not a CD40 antagonist.

Exemplary anti-PD-L1 antibodies that can be used in the methods described herein include those that bind to human PD-L1; NCBI accession numbers NP _001254635.1, NP _001300958.1, and NP _054862.1 provide exemplary PD-L1 protein sequences. Exemplary antibodies are described in U.S. publication nos. 2017/0058033; international publication nos. WO 2016/061142a 1; WO 2016/007235a 1; WO 2014/195852a 1; and WO 2013/079174a1, including, for example, BMS-936559(MDX-1105), FAZ053, KN035, avizumab (Tecentriq, MPDL3280A), avizumab (Bavencio), and dervacizumab (Durvalumab) (infinzi, MEDI-4736).

In some embodiments, immunotherapy can antagonize cell surface receptors to enhance anti-cancer immune responses. For example, antagonistic monoclonal antibodies that enhance the immune response against cancer may include antibodies that target CTLA-4 (ipilimumab, see Tarhini and Iqbal (2010) Onco Targets The.3: 15-25 and U.S. Pat. No. 7,741,345, or tremelimumab (tremelimumab)) or antibodies that target PD-1 (nivolumab, Topalian et al (2012) N.Engl.J.Med.366(26):2443-54 and International publication No. WO 2013/173223, pembrolizumab/MK-3475, and pidilizumab (CT-011)).

Some immunotherapy approaches enhance the ability of T cells to recruit to the tumor site (e.g., blockade of endothelin receptor a/B (ETRA/B), e.g., with Macitentan (Macitentan) or a combination of ETRA and ETRB antagonists BQ123 and BQ788, see Coffman et al (2013) Cancer Biol ther.14(2):184-92), or enhance CD 8T cell memory formation (e.g., with rapamycin and metformin, see, e.g., Pearce et al (2009) Nature 460(7251): 103-7; Mineharu et al (2014) mol. Cancer ther.13(12): 3024-36; and berezhney et al (2014) Oncoimmunology 3: e 28811). Immunotherapy may also include the administration of one or more of: adoptive Cell Transfer (ACT), which involves transferring autologous or allogeneic tumor-responsive lymphocytes expanded ex vivo, such as dendritic cells or peptides with adjuvants; cancer vaccines, such as DNA-based vaccines, cytokines (e.g., IL-2), cyclophosphamide, anti-interleukin 2R immunotoxins, and/or prostaglandin E2 inhibitors (e.g., using SC-50). In some embodiments, the method comprises administering a composition comprising tumor-pulsed dendritic cells, e.g., as described in international publication No. WO 2009/114547 and references cited therein. See also Shiao et al (2011) Genes & Dev.25: 2559-72.

Reduction of tumor protective immunosuppression

In some embodiments, the methods comprise selecting and/or administering a therapy that reduces tumor protective immunosuppression; these therapies may primarily target immunomodulatory cell types, such as regulatory T cells (Tregs) or M2-polarized macrophages, for example, by reducing the number of immunomodulatory cell types, altering their function, or preventing their tumor localization. For example, Treg-targeted therapies include anti-GITR monoclonal antibody (TRX518), cyclophosphamide (e.g., rhythmic dose), arsenic trioxide, paclitaxel, sunitinib (sunitinib), oxaliplatin (oxaliplatin), PLX4720, anthracycline-based chemotherapy, Daclizumab (anti-CD 25); immunotoxins, such as Ontak (denileukin diftotox); lymphodepletion (e.g., chemical or radiolytic lymphodepletion) and drugs that selectively target the VEGF-VEGFR signaling axis, such as VEGF blocking antibodies (e.g., bevacizumab), or inhibitors of VEGFR tyrosine kinase activity (e.g., lenvatinib) or inhibitors of ATP hydrolysis (e.g., using ectonucletidase inhibitors such as ARL67156(6-N, N-diethyl-D- β, γ -dibromomethylene ATP trisodium salt), 8- (4-chlorophenylthio) cAMP (pCPT-cAMP) and related cyclic nucleotide analogs (8- [ 4-chlorophenylthio ] cGMP; pCPT-cGMP) and those described in international publication No. WO 2007/135195, as well as monoclonal antibodies (mabs) directed against CD73 or CD 39). Docetaxel (Docetaxel) also had an effect on M2 macrophages. See, e.g., Zitvogel et al (2013) Immunity 39: 74-88.

In another example, M2 macrophage targeting therapies include clodronate-liposomes (Zeisberger, et al (2006) br.j.cancer 95:272-81), DNA-based vaccines (Luo et al (2006) j.clin.invest.116(8):2132-41), and M2 macrophage targeting pro-apoptotic peptides (Cieslewicz et al (2013) proc.natl.acad.sci.u.s.a.110(40): 15919-24). Macrophages can also be targeted using: CSF-1R inhibitors (e.g., PLX3397, AMG820 IMC-CS4/LY3022855, or RG7155/RO5509554) or other small molecule or blocking monoclonal antibodies (e.g., anti-CD 11b (e.g., Rovelizumab)), CCL2 (e.g., Carluumab), ANG2 (e.g., Nelsavizumab (Nesvacumab)), IL4 (e.g., Pascolizumab)), IL4-Ra (e.g., Dupimumab)), IL13 (e.g., Ribrizumab (Lebrikizumab), Tranlizumab (Tranlizumab), GSK679586), ab Fc γ R (e.g., Rituximab (Rituximab) (CD 20); Ibrutinib (Ibrutizumab) (Syk), R788 (Sykk), neurone 679586 (e.g., Rituximab), Sirtuzumab (e.g., Sirtuzumab), Sirtuzumab (E.g., Sirtuzumab), IL 8678, E.g., Sirtuzumab), and E, Sariluzumab (Sarilumab)); TNF-a (e.g., MAPK inhibitors such as Adalimumab (Adalimumab), Certolizumab (Certolizumab), Etanercept (Etanercept), Golimumab (golimab), Infliximab (Infliximab)); or CD40 (e.g., CP-870,893). See, e.g., Ruffell and Coussens, Cancer cell.2015, 4 months and 13 days; 462 (27) (4) 472) and references cited therein.

Some useful immunotherapies are directed against the metabolic processes of immunity, and include adenosine receptor antagonists and small molecule inhibitors, such as istradefylline (KW-6002) and SCH-58261; indoleamine 2, 3-dioxygenase (IDO) inhibitors, such as small molecule inhibitors (e.g., 1-methyl-tryptophan (1MT), 1-methyl-D-tryptophan (D1MT), and Toho-1) or IDO-specific sirnas, or natural products (e.g., brassinomin or exiguamine) (see, e.g., Munn (2012) front. biosci. (Elite Ed. 4:734-45) or monoclonal antibodies that neutralize IDO metabolites, such as mabs against N-formylkynurenine.

In some embodiments, immunotherapy can antagonize the effects of cytokines and chemokines, such as IL-10, TGF- β, IL-6, CCL2, and other factors associated with immunosuppression in cancer. For example, TGF- β neutralizing therapies include anti-TGF- β antibodies (e.g., non-hematoxylin mab (fresolimumab), infliximab, ledellimumab (lerdelimumab), GC-1008), antisense oligodeoxynucleotides (e.g., trabedersen), and small molecule inhibitors of TGF- β (e.g., LY2157299) (wojtowwicz-Praga (2003) invest. new Drugs 21(1): 21-32). Another example of a therapy that antagonizes immunosuppressive cytokines may include anti-IL-6 antibodies (e.g., cetuximab) (Guo, et al, Cancer Treat Rev.38(7):904-910 (2012)) also mAbs directed to IL-10 or its receptor may be used, such as those humanized versions described in Llorente et al, Arthritis & Rheumatosis, 43(8): 1790-1800,2000 (anti-IL-10 mAb), or Newton et al, Clin Exp Immunol.2014Jul; 177(1):261-8 (anti-interleukin 10R1 monoclonal antibody) also mAbs directed to CCL2 or its receptor may be used.

In some embodiments, immunotherapy may include agents that are believed to elicit "danger" signals, such as "PAMPs" (pathogen-associated molecular patterns) or "DAMPs" (damage-associated molecular patterns) that stimulate an immune response against cancer. See, e.g., Pradeu and Cooper (2012) Front immunol.3: 287; Escamilla-Tilch et al (2013) Immunol.cell.biol.91(10): 601-10. In some embodiments, immunotherapy may agonize toll-like receptors (TLRs) to stimulate an immune response. TLR agonists include, for example, vaccine adjuvants (e.g., 3M-052) and small molecules (e.g., imiquimod, muramyl dipeptide, CpG, and mifamurtide), as well as coriolus versicolor polysaccharide and endotoxin. See Galluzi et al (2012) Oncoimmornol.1 (5):699-716, Lu et al (2011) Clin. cancer Res.17(1): 67-76, and U.S. Pat. Nos. 8,795,678 and 8,790,655. In some embodiments, immunotherapy may involve the administration of cytokines that elicit immune responses against cancer, see Lee & Margolin (2011) Cancers 3: 3856-93. For example, the cytokine IL-12 may be administered (Portielje et al (2003) Cancer Immunol. Immunother.52:133-44) or as gene therapy (Melero et al (2001) Trends Immunol.22(3): 113-5). In another example, an Interferon (IFN), such as IFN γ, may be administered as an adjunct therapy (Dunn et al (2006) nat. Rev. Immunol.6: 836-48).

Pharmaceutical composition

The methods described herein may include administering pharmaceutical compositions and formulations comprising therapeutic agents described herein.

In some embodiments, the composition is formulated with a pharmaceutically acceptable carrier. The pharmaceutical compositions and formulations may be administered parenterally, topically, orally or by topical administration, for example by aerosol or transdermal administration. The pharmaceutical compositions may be formulated in any manner and may be administered in a variety of unit dosage forms depending on the condition or disease and extent of the disease, the general medical condition of each subject, the resulting preferred method of administration, and the like. Details regarding The formulation and administration techniques of pharmaceuticals are well described in The scientific and patent literature, e.g., see Remington, The Science and Practice of Pharmacy, 21 st edition, 2005.

The therapeutic agent may be administered in the pharmaceutical composition as a single active agent or in combination with other active agents. The compositions may be formulated for administration in human or veterinary medicine in any convenient manner. Wetting, emulsifying and lubricating agents, such as sodium lauryl sulfate and magnesium stearate, as well as coloring, releasing, coating, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition.

Formulations of the compositions include those suitable for intradermal, inhalation, oral/intranasal, topical, parenteral, rectal, and/or intravaginal administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. The amount of active ingredient (e.g., therapeutic agent) that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration, e.g., intradermal, parenteral, intravenous, or by inhalation. The amount of active ingredient combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

The pharmaceutical formulations of the present invention may be prepared according to any method known to the art for the manufacture of medicaments and may contain sweetening agents, flavoring agents, coloring agents and preserving agents. The formulations may be mixed with non-toxic pharmaceutically acceptable excipients suitable for manufacture. The formulations may contain one or more diluents, emulsifiers, preservatives, buffers, excipients, etc., and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, patches, implants, etc.

Pharmaceutical formulations for oral administration may be formulated using pharmaceutically acceptable carriers well known in the art in appropriate and appropriate dosages. Such carriers enable the drug to be formulated as tablets, pills, powders, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions and the like, in unit dosage forms suitable for ingestion by a subject. Pharmaceutical preparations for oral use can be formulated as solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable further compounds, if desired, to obtain tablets or dragee cores. Suitable solid excipients are carbohydrate or protein fillers including, for example, sugars including lactose, sucrose, mannitol, or sorbitol; starches from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropyl methyl cellulose, or sodium carboxymethyl cellulose; and gums including acacia and tragacanth; and proteins such as gelatin and collagen. Disintegrating or solubilizing agents may be added, such as cross-linked polyvinylpyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Push-fit capsules (push-fit capsules) may contain the active agent in admixture with fillers or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active agent may be dissolved or suspended in a suitable liquid, for example, fatty oils, liquid paraffin, or liquid polyethylene glycols with or without stabilizers.

The aqueous suspension may comprise the active agent (e.g., a nucleic acid sequence of the present invention) mixed with a suitable carrier for the manufacture of an aqueous suspension, for example, for use in an aqueous intradermal injection. Such excipients include suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally-occurring phosphatide (e.g. lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g. polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g. heptadecenoxycetyl alcohol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g. polyoxyethylene sorbitol monooleate), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g. polyoxyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents and one or more sweetening agents, for example sucrose, aspartame or saccharin. The permeability of the formulation can be adjusted.

In some embodiments, the oil-based medicament is for administration of a therapeutic blocking agent described herein. Oil-based suspensions may be formulated by suspending the active agent in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these. See, e.g., U.S. patent No. 5,716,928, which describes the use of essential oils or essential oil components to increase the bioavailability of orally administered hydrophobic pharmaceutical compounds and reduce inter-and intra-individual variability (see also U.S. patent No. 5,858,401). The oil suspension may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents may be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These preparations can be preserved by adding an antioxidant such as ascorbic acid. See Minto (1997) J.Pharmacol.Exp.Ther.281:93-102 as an example of an injectable oil medium.

The pharmaceutical formulation may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil or a mineral oil, as described above, or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums, for example gum acacia and gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. Emulsions may also contain sweetening agents and flavoring agents, such as in the preparation of syrups and elixirs. Such formulations may also contain a demulcent, a preservative or a coloring agent. In alternative embodiments, the injectable oil-in-water emulsions of the invention comprise paraffin oil, sorbitan monooleate, ethoxylated sorbitan monooleate and/or ethoxylated sorbitan trioleate.

The pharmaceutical compounds can also be administered by intranasal, intraocular, and intravaginal routes, including suppositories, insufflation, powders, and aerosols (e.g., steroid inhalants, see, e.g., Rohatagi (1995) J. Clin. Pharmacol.35: 1187-1193; Tjwa (1995) Ann. allergy Asthma immunol.75: 107-111). Suppositories can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at body temperature and will therefore melt in the body to release the drug. Such materials are cocoa butter and polyethylene glycols.

In some embodiments, the pharmaceutical compound may be delivered transdermally by a topical route, formulated as a stick, solution, suspension, emulsion, gel, cream, ointment, paste, gel, paint, powder, and aerosol.

In some embodiments, the pharmaceutical compound may also be delivered as microspheres for slow release in vivo. For example, microspheres may be administered by intradermal injection of a slow subcutaneous release drug. See Rao (1995) J.Biomater Sci.Polym.Ed.7: 623-; as biodegradable and injectable gel formulations, see, for example, Gao (1995) pharm. Res.12:857-863 (1995); or as microspheres for oral administration, see, e.g., Eyles (1997) J.Pharm.Pharmacol.49: 669-674.

In some embodiments, the pharmaceutical compound may be administered parenterally, for example by Intravenous (IV) administration or into a body cavity or lumen of an organ. These formulations may comprise a solution of the active agent dissolved in a pharmaceutically acceptable carrier. Among the acceptable vehicles (vehicle) and solvents that may be used are water and Ringer's solution (an isotonic sodium chloride). In addition, sterile fixed oils may be employed as a solvent or suspending medium (medium). For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. These solutions are sterile and generally free of undesirable substances. These formulations may be sterilized by conventional, well-known sterilization techniques. The formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and the like. The concentration of active agent in these formulations can vary widely and will be selected primarily based on body fluid volume, viscosity, body weight, and the like, according to the particular mode of administration selected and the needs of the subject. For IV administration, the formulation may be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. The suspension may be formulated with such suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol. Administration may be by bolus injection or continuous infusion (e.g., substantially uninterrupted introduction into the blood vessel over a specified period of time).

In some embodiments, the pharmaceutical compounds and formulations may be lyophilized. Stable lyophilized formulations comprising oligonucleotides can be prepared by lyophilizing a solution comprising a drug of the invention and a bulking agent, such as mannitol, trehalose, raffinose, and sucrose, or mixtures thereof. A process for preparing a stable lyophilized formulation may include lyophilizing about 2.5mg/mL protein, about 15mg/mL sucrose, about 19mg/mL NaCl, and a sodium citrate buffer at a pH greater than 5.5 but less than 6.5. See, for example, us 20040028670.

Compositions and formulations may be delivered by use of liposomes. By using liposomes, particularly those with ligands specific for target cells on the surface of the liposome, or preferentially to specific organs, active agents can be delivered to target cells in vivo in a concentrated manner. See, for example, U.S. patent nos. 6,063,400; 6,007,839, respectively; Al-Muhammed (1996) J.Microencapsul.13: 293-306; chonn (1995) Curr. Opin. Biotechnol.6: 698-708; ostro (1989) am.J.Hosp.pharm.46: 1576-1587. As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in a bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles having a membrane formed from a lipophilic material and an aqueous interior containing the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form stable complexes. The pH sensitive or negatively charged liposomes are believed to capture DNA rather than complex with it. Both cationic and non-cationic liposomes have been used to deliver DNA to cells.

Liposomes may also include "sterically-stabilized" liposomes, i.e., liposomes containing more than one particular lipid. When incorporated into liposomes, these specific lipids result in an increased circulation lifetime of the liposomes relative to liposomes lacking such specific lipids. Examples of sterically stabilized liposomes are those in which a portion of the vesicle-forming lipid portion of the liposome comprises more than one glycolipid or is derivatized with more than one hydrophilic polymer, such as a polyethylene glycol (PEG) moiety. Liposomes and their use are further described in U.S. Pat. No. 6,287,860.

The formulations of the invention may be administered for prophylactic and/or therapeutic treatment. In some embodiments, for therapeutic applications, the composition is administered to a subject at risk for or having a disorder described herein in an amount sufficient to cure, alleviate, or partially arrest the clinical manifestations of the disorder or its complications; this may be referred to as a therapeutically effective amount.

The amount of the pharmaceutical composition sufficient to accomplish this is a therapeutically effective dose. The dosage regimen and the amount, i.e., dosage regimen, effective for this use will depend upon a variety of factors including the stage of the disease or condition, the severity of the disease or condition, the general state of health of the subject, the physical condition of the subject, and the age and the like. The mode of administration is also considered when calculating the dosage regimen for a subject.

The dosage regimen also takes into account pharmacokinetic parameters well known in The art, i.e., absorption, bioavailability, metabolism, clearance, etc., of The active agent (see, e.g., Hidalgo-Aragens (1996) J. Steroid biochem. mol. biol.58: 611-617; Groning (1996) Pharmazie 51: 337-341; Fotherby (1996) content 54: 59-69; Johnson (1995) J. Pharm. Sci.84: 1144-1146; Rohatagi (1995) Pharmazie 50: 610-613; Brophy (1983) Eur. J. Clin. Pharmacol.24: 103-108; Remington: The Science and Practice of Pharmacy, 21 st edition, 2005). The level of skill allows the clinician to determine the dosage regimen for each individual subject, active agent, and disease or condition being treated. The guidelines provided for similar compositions for use as medicaments may be used as guidelines for determining the dosage regimen, i.e. the dosage regimen and dosage level administered in carrying out the method of the invention, are correct and appropriate.

The formulation may be administered, for example, in single or multiple administrations according to: the dosage and frequency required and tolerated by the subject, the extent and amount of therapeutic effect produced after each administration (e.g., effect on tumor size or growth), and the like. The formulation should provide a sufficient amount of the active agent to effectively treat, prevent, or ameliorate a condition, disease, or symptom (e.g., cancer).

Examples

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Example 1

All bound RNA-ISH and IHC assays were performed as follows: monoclonal antibodies to immune cells (T cell subsets CD3, CD4, CD8, FOXP 3; macrophage CD68, CD 163; B cell CD 20; NK cells CD16, CD56) and RNA ISH probes for repeat RNA (HSATII, HERV-K, HERV-H, LINE1) were applied sequentially to single tissue sections and the antibodies were shown using a contrasting chromogen: brown (diaminobenzidine [ DAB ]) indicates the immune markers and RNA: red (fast red) indicates repeat RNA. Paraffin-embedded sections were mounted on coated slides and placed in an oven at 60 ℃ for 60 minutes. A sequential double staining protocol was performed using a Leica Bond Rx automated immunostaining instrument. Paraffin removal (View RNA Dewax1 protocol) and on-board antigen retrieval were performed at approximately 100 ℃ for 20 minutes using HIER2 reagent as a proprietary Leica solution based on EDTA (pH 8.0-8.5). Monoclonal antibodies for each immune cell subpopulation were diluted in Leica antibody dilutions according to protocol. For the ISH section, the View-RNA eZL detection kit (Affymetrix) was used with BDZ 6.0 software (Leica Biosystems) in Bond RX immunohistochemistry and ISH staining system. Bond RX user option settings for part 2 are as follows: ViewRNA eZ-1 assay 1-plex (Red) protocol; ViewRNA Dewax1 preparation protocol; viewrnase 2 (10); the ViewRNA probe was hybridized for 3 hours, and at these settings, the RNA exposure conditions for FFPE tissue consisted of: incubate with proteinase K in Bond enzyme pretreatment kit at 1:1000 dilution (Leica Biosystems) for 10 min. RNA repeat Ez probe was diluted 1:40 in ViewRNA probe dilution (Affymetrix). After the run, the slides were rinsed with water, air dried at room temperature for 30 minutes, then mounted using a Dako ultra mount (Dako, Carpinteria, CA) and viewed using a standard high brightness microscope. Punctate red hybridization signals in the cytoplasm and nucleus were defined as positive signals for repeat RNAs, and brown cytoplasmic responsiveness in lymphocytes was considered positive for the immune markers.

Example 2

The field of immunotherapy has found that CD8+ T cell infiltration is often associated with the response of immunotherapy (CTLA4 or PD1/PDL1) (Taube JM et al Mod pathol.2017 Dec 1.doi: 10.1038/modpathol.2017.156). FOXP3+ regulatory T cells are thought to block anti-tumor T cell responses, although the discrepancy between the data is greater (see, e.g., Manjili and Butler, Immunol invest.2016 Nov; 45(8): 759-.

We predict that HSATII low tumors are associated with high CD 8T cell infiltration, while HERV-H high tumors are associated with low FOXP3+ cells, which respond most strongly to immunotherapy.

As shown herein, HSATII low melanoma responds to immunotherapy, including anti-PD 1/PDL1 and anti-CTLA 4 therapies (figure 5). Briefly, an HSATII RNA-ISH in combination with CD 3T cell IHC assay was used to evaluate a panel of 20 melanoma patients receiving anti-PD 1/PDL1 or anti-CTLA 4 therapy with Formalin Fixed Paraffin Embedded (FFPE) tissue. The HSATII RNA level (high vs low) and CD 3T cell infiltration of the tumor were assessed by the pathologist manually counting the quantification of cells in the 400x200 micron area. CD 3T cell infiltration was significantly lower in HSATII high vs low tumors (p < 0.02). A correlation between HSATII expression and immunotherapy response was determined according to standard clinical imaging criteria (CT scan changes), where HSATII low tumors responded to these checkpoint immunotherapy drugs, and HSATII high tumors did not respond to these checkpoint immunotherapy drugs.

Furthermore, the data indicate that in the human colon Cancer group, HSATII high signal is positively correlated with CD163+ tumor-associated macrophages (FIGS. 6 and 7), which are typically associated with immunosuppressive or non-responsive tumor microenvironments (Ruffell and Coissns, Cancer cell.2015 Apr 13; 27(4): 462-. Briefly, primary colon cancer on tissue microarrays was stained with HSATII RNA-ISH in combination with CD163 macrophage IHC assay. The HSATII RNA level (high vs low) and CD163 macrophage infiltration of the tumor were assessed by quantification of the pathologist manually counting cells in the 400x200 micron area. CD163 macrophages were significantly higher in HSATII high colon cancer (×) p < 0.0001.

Example 3

HSATII and CD163+ macrophages were positively correlated in Pancreatic Ductal Adenocarcinoma (PDAC). High expression of HSATII was associated with higher CD163+ macrophages. Thus, HSATII in tumor cells is a surrogate marker for macrophage infiltration and can be used to select patients for drugs that target macrophages in the tumor immune microenvironment. This finding is consistent with the colon cancer data in fig. 6 and 7.

Quantification of CD8+ T cells in PDAC tumors differentiated by HSATII high (high, medium) and low (low, negative) expression by IHC is shown (fig. 8).

Example 4

HSATII and CD8+ T cells were negatively correlated in pancreatic ductal adenocarcinoma (figure 9), intrahepatic cholangiocarcinoma (figure 11), and hepatocellular carcinoma (figure 12), demonstrating that this marker could serve as a surrogate for cytolytic immune cell infiltration, which would help identify tumors suitable for immune checkpoint inhibition (anti-CTLA 4 and/or anti-PD 1/PDL 1). This expands published data on colon cancer (Solovyov et al Cell Reports 2018).

Quantification of CD 8T cells was performed in PDAC (fig. 10) and ICC (fig. 13) tumors differentiated by HSATII high (high, medium) and low (low, negative) expression.

Example 5

Experimental procedure

We selected 38 samples from TCGA with total RNA frozen solid tumor RNA-Seq data. These samples consisted of 12 LUAD, 10 COAD, 5 BRCA, 4 KIRC, 4 UCEC, 3 BLCA tumors. Of these 38 samples, 29 samples had matching poly (A) RNA-Seq data. Both total RNA and poly (A) prepared aliquots were from the same physical sample. These samples consisted of 11 LUAD, 6 COAD, 5 BRCA, 4 KIRC, 3 BLCA tumors. The presence of such paired samples allows a technical comparison of the sequencing protocol and its effect on the calculated gene expression.

Total RNA and poly (A) preparation protocols used different ribosomal RNA (rRNA) depletion strategies. Total RNA protocol rRNA was removed using a RiboZero kit. poly (a) uses the poly (a) capture procedure to isolate polyadenylated transcripts, thereby excluding rRNA. After preliminary mass filtering, we aligned reads of the human genome with reads of the Repbase database of repeat elements (Bao et al, 2015). The number of reads mapped to annotated genomic features was quantified and expression was calculated.

Gene expression in samples was calculated and normalized in log2-CPM (counts per million reads) using the TMM method applied in calc normfactors function of edgeR package (Robinson et al, 2010). Only the encoding gene was used for normalization. In particular, this process ensures that the computational subtraction of rRNA reads is completed. The purpose of the normalization procedure is to determine some reference amount (e.g., housekeeping gene expression) that can be compared between different samples to establish a sample-specific normalization factor. In particular, the TMM normalization program assumes that most genes are not differentially expressed, or that the effects of over-expression and under-expression are approximately equal, except for certain outliers. These assumptions are reasonable when we consider scheme-specific differences in the encoding genes. Indeed, most of the encoded genes are expected to be detected by both schemes, whereas the repetitive elements are not. Underexpressed genes (genes with no at least 10 reads per million reads in at least two samples) were filtered out. The same protocol was used for all data sets.

The difference in computational expressions between the two schemes is calculated using a limma package (Smyth, 2004; Ritchie et al, 2015). The expression data is used in conjunction with weights calculated by voom transformation (Law et al, 2014). Although the same computational program (e.g., paired t-tests as implemented in limma software package) was used, this "differential expression" test measures the technical differences between the two sequencing protocols, rather than the biological differences between the individual tissues. The difference is expressed as a binary logarithm of the fold change (logFC).

The variance of the calculated gene expression was subjected to chi-square test as follows. We only considered genes whose median expression exceeded log2(10) using both the poly (a) and total RNA protocols. For each solid sample, we calculated the difference between the expression values of the poly (A) protocol and the total RNA protocol. Then, we calculate the variance of these differences. We performed a chi-square test on the variances to verify whether these differences were independent of the sample. We require that a fold-linear change between FC-2 is detectable for two biological conditions (e.g. tumor and normal tissue), we assume n-3 repeats for each condition. This results in a cut-off of the variance used in the test. Adjusted p-value (FDR) was calculated using Benjamini & Hochberg method.

We performed a linear regression analysis between the variance and the log of the repeat length in the genome. For rank-related ρ, we performed linear regression analysis (logistic regression analysis) between log ((1+ ρ)/(1- ρ)) and log of repeat length in the genome.

Clustering based on expression repeat elements was performed as follows. We created 1000 pilot datasets and clustered on each dataset. After that, we compute a consistency cluster. Entropy forces acting on sequence motifs were calculated using the method developed in (Greenbaum et al, 2012).

Gene ontology enrichment analysis was performed using the web tool provided by PANTIER (Thomas et al, 2003; Mi et al, 2009). We used the "GO bioprocess completion" annotation set (GO ontology database retrieved in 2017 at 26.1.7) with the pantoher overexpression test (version 20160715) and performed bang feroni correction.

GSEA analysis was performed using a pre-sequenced gene list. The genes in the list are ranked according to the t statistic in differential expression analysis. This list includes all expressed genes, not necessarily differentially expressed genes. We acknowledge that we used gene set enrichment analysis, GSEA software, and the molecular characterization database (MsigDB), http:// www.broad.mit.edu/GSEA/(Subramanian et al, 2005).

Results

ERV class expression may be associated with a positive anti-PD-L1 immunotherapy response.

Preexisting tumor T-cell inflammation can be a strong predictor of cancer immunotherapy response to antibodies such as anti-PD-L1/PD-1 or anti-CTLA-4 (Chen et al Nature 2017,541: 321-. Several recent studies have highlighted the link between tumor ERV expression, expression of "viral defense genes" and anti-tumor responses (Chiapinelli et al Cell 2015,162, 974-. We hypothesized that chemically-induced epigenetic dysregulation in tumors leads to expression of ERVs, which in turn stimulate innate immunity PRRs and generate anti-tumor innate immune responses. In one of these studies (Chiapinelli et al 2015), the presence of endogenous ERV was correlated with clinical benefit in patients treated with anti-CTLA-4 therapy. We examined one of the few available tumor immunotherapy RNA-seq datasets from PD-L1 blocking treated patients (Snyder et al 2017). In this group of urothelial cancer patients, we tested the hypothesis that ERV expression is also associated with clinical benefit of therapy. In contrast to previous anti-CTLA 4 studies, we first performed this assay in anti-PDL 1 treated tumors.

We used the repeatmasker/Repbase annotation for hierarchical clustering with expression of ERV repeats, revealing two distinct clusters of high and low ERV expression levels. In this case, there was a significant association between ERV repeat expression and patient response to PD-L1 immunotherapy (p ═ 0.024, Fisher exact test). Thus, patient survival analysis indicated that high expression of ERV repeats correlated with overall survival (fig. 14B, p 0.012) and progression-free survival (fig. 14C, p 0.025). We performed logistic regression analysis of clinical benefit with total ERV repeat expression,

where E _ ERV is the total expression of ERV repeats and p is the likelihood of clinical benefit. The coefficient of E _ ERV is significant (p value 0.04).

We performed Cox regression analysis of overall survival (risk ═ 2.9 × E)_ERV+0.4 × age +3.2 × met; wherein E_ERVIs the total expression of ERV repeats, age is the age of the patient, when presentMet is 1 at liver metastasis, otherwise 0). E_ERVAnd the coefficient of met is significant (p 0.001 and p 0.003). We performed Cox regression analysis for progression-free survival (risk ═ -1.5 × E)_ERV-1.9 age +1.8 mets). E_ERVAnd the coefficient of met is significant (p ═ 0.009 and p ═ 0.02). In both cases, we examined the proportional risk hypothesis, which holds true.

Interestingly, expression of ERV repeats was a better predictor of immune therapy response compared to viral defense markers in this group, and the study did not divide patients in a similar manner (fig. 14A). We performed a series of Cox regression analyses on the risk ratio using the patient's age, the presence of liver metastases, and the expression of one of the viral defense genes or ERVs as independent variables. The effect of ERV expression was associated with increased survival and was statistically significant (p 0.001, FDR 0.02). The effect of the viral defense genes was not statistically significant. Furthermore, as we show, the repeat maker/Repbase annotation of ERV repeats produces a higher number of reads than the ERV gene annotated in Ensembl, so we suggest that clinical studies reveal more accurate associations by interrogating the overall repeat expression of classes of specific repeat sequences, rather than the specific ERV gene annotated in Ensembl or its related immune classes. It is worth mentioning that the read count for the ERV gene annotated in Ensembl is below the threshold of the standard 10 reads per million for RNA-Seq, ERV3 and ERV3K with the highest number of reads. Expression of these two genes correlates with average ERV expression. This suggests that due to the large number of transcriptions of the repetitive elements, they are more reliable predictors of response to immunotherapy than expression of the relevant immune genes, which would require larger sample sizes to solve the same type of studies.

In addition, we investigated the data set (Hugo et al) and performed a similar series of Cox regression analyses using age, non-synonymous mutation number, and expression of one of the viral defense genes or ERVs as independent variables. Neither viral defense genes nor expression of ERVs had a statistically significant effect on the hazard ratio. Notably, unlike the dataset of (Snyder et al), almost all tumors in this dataset were metastatic. Also, this data set is for melanoma, and the ERV expression patterns are different compared to urothelial cancer, which makes their presence more difficult to assess. Taken together, this suggests that there are distinct repeat classes associated with different phenotypes that are tissue background related and worthy of further investigation.

Other embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (19)

1. A method of treating cancer in a subject, the method comprising: providing a sample comprising cells from the cancer; detecting the level of repetitive RNA (eg, HSATII, LINE-1, HERV-K, HERV-H) in the cells; comparing the level of repetitive RNA in the sample to a reference level; and Selecting and optionally administering a treatment comprising one or both of the following: (i) reducing the export level of the repetitive RNA in the cell or increasing the cell or (ii) immunotherapy to reduce tumor-protective immunosuppression. 2. The method of claim 1, wherein the treatment that reduces the export level of the repetitive RNA in the cell or increases the level of the repetitive RNA in the cell is an inhibitory nucleic acid targeting the repetitive RNA, the inhibitory nucleic acid targeting the repetitive RNA It is preferably selected from the group consisting of locked nucleic acid (LNA) molecules, short hairpin RNA (shRNA) molecules, small inhibitory RNA (siRNA) molecules, antisense nucleic acid molecules, peptide nucleic acid molecules and morpholino. 3. The method of claim 1, wherein the export level of repetitive RNA in the cell or the treatment that increases the level of repetitive RNA in the cell is a reverse transcriptase inhibitor (RTI) selected from the group consisting of The group consisting of: nucleoside analog reverse transcriptase inhibitors, nucleotide analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and combinations thereof. 4. The method of claim 3, wherein the nucleoside analog reverse transcriptase inhibitor comprises lamivudine, abacavir, zidovudine, emtricitabine, didanosine, Tavudine, entecavir, alitabine, sensavudine, zalcitabine, dexamethasone, amdoxovir, efcitabine, fertinavir, laxivir, stapidin, or a combination thereof. 5. The method of claim 3, wherein the non-nucleoside reverse transcriptase inhibitor comprises lesivirine, rilpivirine, efavirenz, etravirine, doravirine, dapivir Lin, or a combination thereof; or wherein the nucleotide analog reverse transcriptase inhibitor comprises tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir, or a combination thereof. 6. The method of claim 1, wherein the treatment that reduces the export level of repetitive RNA in the cell or increases the level of repetitive RNA in the cell comprises a cytidine analog or a guanosine analog. 7. The method of claim 1, wherein the treatment that reduces the export level of repetitive RNA in the cell or increases the level of repetitive RNA in the cell comprises an HDAC inhibitor; a BET inhibitor; or a DNA hypomethylating agent. 8. The method of claim 7, wherein the DNA hypomethylating agent is azacytidine, decitabine, cladribine, or a combination thereof; the HDAC inhibitor is suberoylanilide Hydroxamic acid (SAHA/Vorinostat/Ronglixa), trichostatin A (TSA), PXD-101, lipopeptide, MS-275, MGCD0103, valproic acid, or sodium phenylbutyrate, Or the BET inhibitor is (+)-JQ1, I-BET762, OTX015, I-BET151, CPI203, PFI-1, MS436, CPI-0610, RVX2135, FT-1101, BAY1238097, INCB054329, TEN-010, GSK2820151 , ZEN003694, BAY-299, BMS-986158, ABBV-075, GS-5829, or PLX51107. 9. The method of claim 1, comprising administering a treatment comprising one or both of the following: (i) reducing the export of repetitive RNAs in the cell within a time sufficient to reduce the repeat level below a subsequent reference level A treatment that increases levels or levels of repetitive RNAs in cells, or (ii) an immunotherapy that reduces tumor-protective immunosuppression, followed by administering to the subject a treatment comprising immunotherapy that enhances anti-tumor immunity, wherein initial and subsequent The reference levels can be the same or different. 10. The method of claim 9, wherein the immunotherapy to enhance anti-tumor immunity comprises an immunotherapeutic agent selected from the group consisting of: anti-PD-1 antibody, anti-PD-L1 antibody, anti-CD137 antibody, anti-PD-1 antibody CTLA4 antibody, anti-CD40 antibody, anti-IL10 antibody, anti-TGF-beta antibody, and anti-IL-6 antibody. 11. The method of any one of claims 1 to 10, wherein administering the treatment results in a reduction in tumor burden in the subject. 12. The method of any one of claims 1 to 11, wherein the cancer is epithelial cancer. 13. The method of claim 12, wherein the epithelial cancer is melanoma, pancreatic cancer, colorectal cancer, breast cancer, prostate cancer, kidney cancer, ovarian cancer, lung cancer, pancreatic cancer, liver cancer, or urinary tract skin cancer. 14. The method of any one of claims 1 to 13, wherein the cancer comprises a mutation in tumor protein p53 (TP53). 15. A method of predicting whether a cancer will respond to treatment comprising immunotherapy that enhances anti-tumor immunity, the method comprising: providing a sample comprising cells from the cancer; detecting the level of repetitive RNA in the cell; and The level of the repetitive RNA in the sample is compared to a reference level; cancers in which the level of repetitive RNA is lower than the reference level may respond to treatment comprising immunotherapy that enhances anti-tumor immunity. 16. A method of predicting whether a cancer will respond to treatment comprising immunotherapy that reduces tumor-protective immunosuppression, the method comprising: providing a sample comprising cells from the cancer; detecting the level of repetitive RNA in the cell; and The level of the repeat RNA in the sample is compared to a reference level; wherein the level of the repeat RNA is higher than the reference level for cancers that may be useful for immunotherapy, inhibitory nucleic acid-targeted repeats comprising reduced tumor-protective immunosuppression RNA, or a reverse transcriptase inhibitor (RTI), selected from the group consisting of: nucleoside analog reverse transcriptase inhibitors, nucleotide analog reverse transcriptase inhibitors, non-nucleoside analog reverse transcriptase inhibitors Glycoside reverse transcriptase inhibitors, and combinations thereof. 17. A method of determining immune cell levels in cancer, the method comprising: providing a sample comprising cells from the cancer; detecting the level of HSATII and/or HERV-H repeat RNA in the cells; and comparing the level of the HSATII and/or HERV-H repeat RNA in the sample to a reference level (eg, in a normal adjacent cell or tissue); in: A cancer with a level of HSATII repeat RNA above said reference level has CD8 T cells in said cancer; Cancers with levels of HSATII repeat RNA at or below the reference level have CD163 macrophages; and Cancers with levels of HERV-H repeat RNA above the reference level had FOXP3 T cells. 18. The method of claim 17, further comprising classifying the cancer as CD8+, CD163+, or FOXP3+ based on the levels of HSATII and/or HERV-H in the cells. 19. The method of claim 13, wherein the epithelial cancer is pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, or hepatocellular carcinoma.

Images